Extension Study of Participants From SPG302-ALZ-101

Status:
ENROLLING_BY_INVITATION

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALZ-101 with mild to moderate Alzheimer's Disease (AD)

PHASE2

Spinogenix